RENAU.UNSP.ARD 1/5 EO-20 (56S0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, RENAU.UNSP.ARD 1/5 EO-20 (56S0) has a cash flow conversion efficiency ratio of 0.047x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€193.30 Million ≈ $225.99 Million USD) by net assets (€4.14 Billion ≈ $4.84 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RENAU.UNSP.ARD 1/5 EO-20 (56S0) balance sheet quality index to measure how much of total assets are equity-financed.
RENAU.UNSP.ARD 1/5 EO-20 - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how RENAU.UNSP.ARD 1/5 EO-20's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check RENAU.UNSP.ARD 1/5 EO-20 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
RENAU.UNSP.ARD 1/5 EO-20 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RENAU.UNSP.ARD 1/5 EO-20 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PTT Exploration and Production Public Company Limited
F:NVAL
|
0.085x |
|
Korea Electric Power Corp
KO:015760
|
0.071x |
|
CSG N.V.
AS:CSG
|
-0.331x |
|
Bank of Beijing Co Ltd
SHG:601169
|
-0.375x |
|
Jde Peets Nv
AS:JDEP
|
0.066x |
|
Akamai Technologies Inc
NASDAQ:AKAM
|
0.074x |
|
Ball Corporation
NYSE:BALL
|
-0.138x |
|
HAL Trust
AS:HAL
|
0.088x |
Annual Cash Flow Conversion Efficiency for RENAU.UNSP.ARD 1/5 EO-20 (2022–2025)
The table below shows the annual cash flow conversion efficiency of RENAU.UNSP.ARD 1/5 EO-20 from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see 56S0 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.13 Billion ≈ $4.82 Billion |
€692.20 Million ≈ $809.25 Million |
0.168x | -17.18% |
| 2024-12-31 | €4.02 Billion ≈ $4.70 Billion |
€815.10 Million ≈ $952.94 Million |
0.203x | -27.43% |
| 2023-12-31 | €2.67 Billion ≈ $3.13 Billion |
€746.40 Million ≈ $872.62 Million |
0.279x | +14.62% |
| 2022-12-31 | €2.51 Billion ≈ $2.94 Billion |
€612.30 Million ≈ $715.84 Million |
0.244x | -- |
About RENAU.UNSP.ARD 1/5 EO-20
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more